SGLT2 inhibitors, like dapagliflozin, empagliflozin, and sotagliflozin, are drugs used primarily to treat type 2 diabetes mellitus by inhibiting the sodium-glucose cotransporter in the proximal convoluted tubules, causing glycosuria, and leading to reduced blood glucose levels [7]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.